Gracell Biotechnologies Inc. (NASDAQ:GRCL) — Market Cap & Net Worth
Market Cap & Net Worth: Gracell Biotechnologies Inc. (GRCL)
Gracell Biotechnologies Inc. (NASDAQ:GRCL) has a market capitalization of $989.87 Million ($989.87 Million) as of October 10, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #8922 globally and #2516 in its home market, demonstrating a -4.73% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Gracell Biotechnologies Inc.'s stock price $562.10 by its total outstanding shares 96572400 (96.57 Million).
Gracell Biotechnologies Inc. Market Cap History: 2026 to 2026
Gracell Biotechnologies Inc.'s market capitalization history from 2026 to 2026. Data shows growth from $54.28 Billion to $54.28 Billion (0.00% CAGR). Check today's stock price for Gracell Biotechnologies Inc. for real-time trading data and today's change.
Gracell Biotechnologies Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Gracell Biotechnologies Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see Gracell Biotechnologies Inc. cash flow conversion for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of GRCL by Market Capitalization
Companies near Gracell Biotechnologies Inc. in the global market cap rankings as of October 10, 2026. See GRCL equity financing ratio to understand what proportion of total assets are financed by equity.
Key companies related to Gracell Biotechnologies Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $129.29 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #366 globally with a market cap of $75.50 Billion USD.
- CSL Ltd (AU:CSL): Ranked #448 globally with a market cap of $63.11 Billion USD ( AU$89.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $129.29 Billion | $510.08 |
| #366 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $75.50 Billion | $746.54 |
| #448 | CSL Ltd | AU:CSL | $63.11 Billion | AU$183.84 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $225.00 |
Gracell Biotechnologies Inc. Historical Marketcap From 2026 to 2026
Between 2026 and today, Gracell Biotechnologies Inc.'s market cap moved from $54.28 Billion to $ 54.28 Billion, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $54.28 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 10th, 2026 the market cap of Gracell Biotechnologies Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $989.87 Million USD |
| MoneyControl | $989.87 Million USD |
| MarketWatch | $989.87 Million USD |
| marketcap.company | $989.87 Million USD |
| Reuters | $989.87 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Gracell Biotechnologies Inc.
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enable… Read more